Related Experiment Video
Updated: Jan 8, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges
Molham Sakkal1,2, Ranim W A Abdelmoteleb1,2, Aya Al Ali1,2
1College of Pharmacy, Al Ain University, PO BOX 64141, Al Ain, United Arab Emirates.
Abstract:
Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Conventional therapies, including surgery, chemotherapy, and targeted treatments, often show limited efficacy, especially in advanced stages. Pulmonary drug delivery systems (PDDSs) have gained attention as an innovative approach for NSCLC management by enabling direct drug administration to the lungs. This method improves therapeutic outcomes while minimizing systemic side effects. Advances in nanotechnology have further enhanced the potential of inhalable chemotherapy, with nanoparticles offering notable benefits such as improved drug solubility, stability, and protection from premature degradation. Additionally, their small size and modifiable surfaces allow for targeted delivery to tumor cells, increasing treatment efficacy and reducing harm to healthy tissues. This review outlines the formulations used in PDDSs for NSCLC, evaluates suitable inhalation devices, and examines the physicochemical characteristics of nanoparticles critical for pulmonary delivery. It also discusses both passive and active targeting mechanisms and explores current challenges in inhalable nanomedicine. Emphasis is placed on recent innovations in inhalable nanomaterials, providing a comprehensive and current perspective on their application in NSCLC therapy.
Insights
Pulmonary drug delivery systems (PDDSs) offer a promising approach for non-small cell lung cancer (NSCLC) treatment. Nanoparticle-based inhalable chemotherapy enhances drug efficacy and reduces side effects by targeting lung tumors directly.
Area of Science:
- Oncology
- Nanotechnology
- Pulmonary Medicine
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Conventional therapies for advanced NSCLC often have limited efficacy and significant systemic side effects.
- Pulmonary drug delivery systems (PDDSs) enable direct lung administration, improving therapeutic outcomes.
Purpose of the Study:
- To review current formulations and devices for PDDS in NSCLC.
- To examine nanoparticle characteristics crucial for pulmonary delivery.
- To discuss targeting strategies and challenges in inhalable nanomedicine for NSCLC.
Main Methods:
- Review of existing literature on PDDS for NSCLC.
- Analysis of nanoparticle formulations and their physicochemical properties.
- Evaluation of inhalation devices and targeting mechanisms (passive and active).
Main Results:
- Nanoparticles enhance drug solubility, stability, and protect against degradation.
- Targeted delivery via nanoparticles increases NSCLC treatment efficacy and minimizes healthy tissue damage.
- Recent innovations in inhalable nanomaterials show significant therapeutic potential.
Conclusions:
- PDDS, particularly using nanotechnology, represents a significant advancement in NSCLC management.
- Optimized nanoparticle characteristics and delivery devices are key for effective pulmonary chemotherapy.
- Addressing current challenges in inhalable nanomedicine is crucial for clinical translation.
